Blog
RSS FeedPosted by Michael Wonder on 10 Jul 2018
Sanofi denounces CADTH negative recommendation on Dupixent
10 July 2018 - Sanofi Genzyme said that it is disappointed with the recent recommendation by CADTH to not reimburse Dupixent, ...
Posted by Michael Wonder on 09 Jul 2018
CADTH publishes final CDEC recommendation for dupilumab
9 July 2018 - CADTH has completed its assessment of Dupixent (dupilumab) for the treatment of patients with atopic dermatitis. ...
Posted by Michael Wonder on 27 Jun 2018
New from CADTH: procedural guidelines and a streamlined therapeutic review framework
27 June 2018 - Recent changes continue to strengthen the Pharmaceutical Reviews portfolio and help CADTH adapt quickly to the changing ...
Posted by Michael Wonder on 17 Apr 2018
CADTH to review CAR T-cell therapies
17 April 2018 - Since the FDA approved the first gene therapy in 2017, Canadian patients, health care providers, and decision-makers ...
Posted by Michael Wonder on 16 Apr 2018
CADTH 2018-2021 strategic plan
16 April 2018 - Dr. Brian O’Rourke, CADTH President and CEO, has released the CADTH 2018-2021 Strategic Plan. ...
Posted by Michael Wonder on 15 Apr 2018
Doctors, drug and tech experts converge on Halifax for symposium
13 April 2018 - As a frontline health-care provider and addictions specialist, Dr. David Martell sees the advent of drug ...
Posted by Michael Wonder on 28 Mar 2018
Adjustment of application fees for CADTH pharmaceutical reviews
28 March 2018 - In February 2018, CADTH announced that beginning in April 2018 application fees for CADTH pharmaceutical reviews ...
Posted by Michael Wonder on 27 Mar 2018
Gene therapy: international regulatory and health technology assessment activities and reimbursement status
28 March 2018 - There is widespread variation in the definition of gene therapy used by international regulatory bodies and a ...
Posted by Michael Wonder on 20 Mar 2018
CADTH calls for nominations
19 March 2018 - CADTH has released a call for nominations to attract qualified candidates to join its advisory and ...
Posted by Michael Wonder on 13 Mar 2018
Price and clinical factors impact Canadian orphan drug recommendation rates
11 March 2018 - Canada’s Common Drug Review (CDR), which provides recommendations on public payer reimbursement for all non-oncology drugs, ...
Posted by Michael Wonder on 08 Mar 2018
CADTH Common Drug Review will accept submissions up to six months pre-Notice of Compliance
8 March 2018 - Operational change can help reduce the time between regulatory approval and reimbursement recommendations for prescription drugs ...
Posted by Michael Wonder on 27 Feb 2018
Sobi’s Orfadin (nitisinone) receives positive reimbursement recommendation for the treatment of HT-1 from CADTH Canadian Drug Expert Committee
27 February 2018 - Sobi announced today that the CADTH Canadian Drug Expert Committee has issued a conditional positive reimbursement ...
Posted by Michael Wonder on 07 Feb 2018
AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Maviret – an oral therapy for the treatment of patients with hepatitis C
6 February 2018 - Maviret previously received a Notice of Compliance from Health Canada on 16 August 2017. ...
Posted by Michael Wonder on 13 Dec 2017
Update on revised process for biosimilars
12 December 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the submission and ...
Posted by Michael Wonder on 11 Dec 2017
Call for feedback: medicine for the management of rheumatoid arthritis
9 December 2017 - A draft report on medicine for the management of rheumatoid arthritis is now available for feedback from ...